Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

The advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI-insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment and are imperative for disease progressi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rebecca Warfvinge, Linda Geironson Ulfsson, Parashar Dhapola, Fatemeh Safi, Mikael Sommarin, Shamit Soneji, Henrik Hjorth-Hansen, Satu Mustjoki, Johan Richter, Ram Krishna Thakur, Göran Karlsson
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2024-11-01
Series:	eLife
Subjects:	leukemic stem cell CITE-Seq CML CD26 CD35 BCR-ABL1
Online Access:	https://elifesciences.org/articles/92074
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predicting drug resistance
by: Nicole S Arellano, et al.
Published: (2024-11-01)

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers
by: Anna Sicuranza, et al.
Published: (2025-05-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
by: Sarah K. Tasian, et al.
Published: (2025-12-01)

Glivec: A New Treatment Modality for CML: A Case History
by: Jürg Zimmermann
Published: (2002-08-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

The Unusual Presentation of Bilateral Proptosis Presents a Dilemma in the Case of Juvenile Myelomonocytic Leukemia
by: Himanshu Gohatre, et al.

Discovery of <i>N</i>-(2-Acetamidobenzo[<i>d</i>]thiazol-6-yl)-2-phenoxyacetamide Derivatives as Novel Potential BCR-ABL1 Inhibitors Through Structure-Based Virtual Screening
by: Shuaixing Wang, et al.
Published: (2025-02-01)

Evaluating the correlation of Age and Gender with the Hematological Parameters of the Chronic Myeloid Leukemia Patients
by: Farooq I. Mohammad, et al.
Published: (2025-04-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01)

Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients
by: Ayşegül Uğur Kurtoğllu, et al.
Published: (2017-05-01)

Utility of leucocyte antigens in distinguishing between bacterial and viral infection in children
by: Anna Stelmaszczyk-Emmel, et al.
Published: (2018-10-01)

Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
by: Irena Philipova, et al.
Published: (2025-07-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Тактика выявления частых и редких типов химерного транскрипта BCR-ABL при хроническом миелоидном лейкозе
by: О. В. Никулина, et al.
Published: (2015-04-01)

The comparative analysis of BCR-ABL/ABL detection by real-time quantitative PCR and automated GeneXpert Dx System in chronic myeloid leukemia patients with major and complete molecular response
by: S. A. Smirnikhina, et al.
Published: (2014-07-01)

Chronic myeloid leukemia in childhood: a case report
by: Uma Bhatta, et al.
Published: (2021-09-01)

BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
by: Caterina Mancini, et al.
Published: (2025-05-01)

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL
by: Wen‐bin Cao, et al.
Published: (2018-06-01)

Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01)

Cytokines secreted from bone marrow-derived mesenchymal stem cells promote apoptosis of CD34+ leukemic stem cells as anti-cancer therapy
by: Raheleh Farahzadi, et al.
Published: (2024-06-01)

Enhanced antibody responses in CD19-Cre mice
by: Diogo M. Cunha, et al.
Published: (2025-01-01)

Fusion genes in cancers: Biogenesis, functions, and therapeutic implications
by: Haiqiong Tang, et al.
Published: (2025-09-01)

In silico development of HASDI-G2 as a novel agent for selective recognition of the DNA sequence
by: Andrii Zaremba, et al.
Published: (2025-03-01)

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase
by: Sekulić Borivoj, et al.
Published: (2022-01-01)

Current and future of targeted therapies against BCR::ABL kinases
by: Sridhar Jayavel, et al.
Published: (2025-04-01)

DPP-IV Inhibition by Solubilized Elastin Peptides from Yellowtail Bulbus Arteriosus Suppresses Ultraviolet-B-Induced Photoaging in Hairless Mice
by: Kumiko Takemori, et al.
Published: (2024-12-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)
by: VV Tikhonova, et al.
Published: (2018-07-01)

Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report
by: Sara Di Giusto, et al.
Published: (2025-08-01)

Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation
by: A. G. Turkina, et al.
Published: (2024-12-01)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
by: ES Kolotova, et al.
Published: (2016-01-01)

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?
by: Cristina Madaudo, et al.
Published: (2025-04-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)